Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.62 USD | +1.26% | +3.35% | -13.18% |
May. 10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
May. 08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.18% | 1.19B | |
+39.89% | 54.04B | |
+43.57% | 41.96B | |
-1.13% | 41.92B | |
-7.59% | 28.35B | |
+12.60% | 26.35B | |
-22.07% | 19B | |
+7.74% | 13B | |
+28.35% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Transcript : Mirum Pharmaceuticals, Inc. - Special Call